<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311232</url>
  </required_header>
  <id_info>
    <org_study_id>2010-11-035</org_study_id>
    <nct_id>NCT01311232</nct_id>
  </id_info>
  <brief_title>Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab</brief_title>
  <official_title>Hepatitis B Virus Reactivation in Asian Patients Treated With Rituximab-containing Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective analysis to identify factors influencing hepatitis B virus&#xD;
      reactivation in patients treated with rituximab containing chemotherapy. Rituximab monoclonal&#xD;
      antibody targeting CD20 induces B-cell depletion resulting in prolonged immune suppression.&#xD;
      This leads to frequent reactivation of patients with a previous history of exposure to HBV or&#xD;
      HBV carrier.&#xD;
&#xD;
      We collect the clinical features and laboratory findings of patients satisfied the inclusion&#xD;
      criteria as follows.&#xD;
&#xD;
        1. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or \ follicular B-cell&#xD;
           lymphoma (FL).&#xD;
&#xD;
        2. Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a&#xD;
           primary treatment&#xD;
&#xD;
        3. Patients with a history of previous exposure to HBV&#xD;
&#xD;
             -  HBV surface antigen (HBs Ag) positive Or&#xD;
&#xD;
             -  HBV core antibody (IgG anti-HBc antibody) positive&#xD;
&#xD;
      Then, we compare the HBV reactivation group with the control group (HBV reactivation does not&#xD;
      happen) to find factors influencing HBV reactivation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of factors associated with Hepatitis B virus reactivation:&#xD;
&#xD;
        -  Laboratory parameters defining HBV status/activity at time of treatment initiation&#xD;
&#xD;
        -  Lymphoma stage at rituximab treatment initiation (Ann Arbor, B-symptoms, bone marrow&#xD;
           involvement, IPI, ECOG-score, LDH)&#xD;
&#xD;
        -  Immunochemotherapy regimen (treatment line, rituximab dose and cycle)&#xD;
&#xD;
        -  Disease status at time of HBV reactivation&#xD;
&#xD;
        -  Antiviral prophylaxis (medication, dose, duration at time at time of reactivation)&#xD;
&#xD;
        -  Patient demographics (age, gender, residence, ethnic origin, smoking status, alcohol&#xD;
           consumption and occupation)&#xD;
&#xD;
      Time to Hepatitis B virus reactivation&#xD;
&#xD;
        -  The time from start of rituximab-containing immunochemotherapy until first evidence of&#xD;
           HBV reactivation meeting the criteria&#xD;
&#xD;
        -  Description of prophylaxis and treatment with antiviral medication HBV vaccination Time&#xD;
           of initiation of antiviral therapy of prophylaxis relating to clinical or laboratory&#xD;
           signs of possible HBV reactivation Anti-viral medication used in prophylaxis or therapy&#xD;
&#xD;
        -  Description of outcomes Outcomes of the HBV reactivation Outcomes of the&#xD;
           rituximab-containing immunochemotherapy Demographics and previous infection history:&#xD;
           Age, gender, nationality, race, social history, past medical history&#xD;
&#xD;
        -  Parameters associated with lymphomas: Ann Arbor stage, number of extranodal involvement,&#xD;
           serum LDH, serum β2-microglobulin, ECOG performance status, presence of B symptoms,&#xD;
           International Prognostic Index, bone marrow invasion&#xD;
&#xD;
        -  Laboratory parameters associated with hepatitis B virus:&#xD;
&#xD;
      hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti- HBs), hepatitis B e&#xD;
      antigen (HBeAg), hepatitis B core antibody (anti-HBc), hepatitis B e antibody (anti-HBe),&#xD;
      serum HBV DNA&#xD;
&#xD;
        -  Lymphoma treatment history:&#xD;
&#xD;
      Line of treatment (first line, second line), rituximab and chemotherapy administration (dose,&#xD;
      schedule), start date, last treatment date&#xD;
&#xD;
        -  Prophylaxis or treatment against HBV reactivation:&#xD;
&#xD;
      antiviral drug (dose, schedule, duration)&#xD;
&#xD;
        -  Hepatitis B virus reactivation:&#xD;
&#xD;
      onset, serologic markers, outcome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2010</start_date>
  <completion_date type="Actual">December 1, 2013</completion_date>
  <primary_completion_date type="Actual">December 1, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatitis B virus reactivation</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma</condition>
  <condition>Patients Treated With Rituximab-CHOP or Rituximab-CVP</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Patients with HBV reactivation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without HBV reactivation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hepatitis B virus positivity and treated with rituximab-containing&#xD;
        chemotherapy to treat their disease, diffuse large B-cell lymphoma or follicular lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or follicular B-cell&#xD;
             lymphoma (FL).&#xD;
&#xD;
          2. Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a&#xD;
             primary treatment&#xD;
&#xD;
          3. Patients with a history of previous exposure to HBV&#xD;
&#xD;
               -  HBV surface antigen (HBs Ag) positive Or&#xD;
&#xD;
               -  HBV core antibody (IgG anti-HBc antibody) positive&#xD;
&#xD;
          4. Patients with documented HBV reactivation (definite or presumptive) occurring during&#xD;
             treatment (at least two cycles of R-CHOP or R-CVP) or within 12 months after the last&#xD;
             dose of rituximab&#xD;
&#xD;
               -  Definitive HBV reactivation&#xD;
&#xD;
                  - Elevation of serum HBV DNA level &gt;1 log IU/mL from baseline or absolute&#xD;
                  increase of HBV DNA by 6 log10 IU/mL in HBsAg positive patients&#xD;
&#xD;
               -  Presumptive HBV reactivation - Increase of ALT (≥3x baseline value or absolute&#xD;
                  value of ≥100 U/L) and positive conversion of HBs Ag in previously HBsAg-negative&#xD;
                  patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had received chemotherapy other than R-CHOP or R-CVP after diagnosis&#xD;
&#xD;
          2. patients diagnosed with HIV, HCV or HDV co-infection&#xD;
&#xD;
          3. Patients who had undergone allogenic stem cell transplantation before hepatitis B&#xD;
             virus reactivation was documented&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hing Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 6, 2011</study_first_submitted>
  <study_first_submitted_qc>March 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rituximab, lymphoma, hepatitis B virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

